Preparations come on the heels of positive results from the Phase II ARC-7 study
News
‘New’ GSK spotlights growth potential of vaccines and speciality medicines
British drugmaker predicted a substantial £33bn sales ambition by 2031 in investor update
Novartis reveals long-term results for MS therapy Kesimpta
B-cell targeting therapy preserved patients’ IgG/IgM levels, with no increased risk of serious infections
Cancer Research UK partners with Aleta Biotherapeutics on blood cancer therapy
Partnership will advance the early clinical development of CAR-T cell engager candidate ALETA-001
NHSX sets out new ‘patient-centred’ data strategy
Strategy includes proposals for patients to easily access their test results, medication lists, procedures and care plans
Gov’t injects £64m into clinical research plan
Funding will go toward the first phase of activity of ‘The Future of UK Clinical Research Delivery’ plan
INTCR delivers another set of hard-fought finals days
The 2021 International Clinical Researcher of the Year virtual finals days took place over the 15th and 16th of June.
US approves Pradaxa as oral blood thinning med for children
First oral blood thinning drug approved for paediatric patients in the US
ABPI launches new Patient Advisory Council
The council will be comprised of senior leaders from the patient charity sector
EU green lights AZ, MSD’s rare disease therapy Koselugo
Drug approved to treat children with neurofibromatosis type 1 and plexiform neurofibromas
NHS England announces extra funding for young people’s mental health services
An extra £40m will go toward enhancing mental health services for children and young people
US approval for OTC use of Bayer’s Astepro
Approval makes Astepro the first and only OTC steroid free antihistamine nasal spray available in the US
Novartis’ radioligand therapy granted US Breakthrough Therapy Designation
Lu-PSMA-617 is a potential treatment for metastatic castration-resistant prostate cancer
Zolgensma shows promise in presymptomatic SMA patients
Children treated with gene therapy prior to symptom presentation achieved motor milestones not seen in the natural history of SMA
EC approves Sanofi’s Aubagio for paediatric MS patients
Aubagio has been authorised for the treatment of paediatric patients aged ten to 17 years living with RRMS
